FDA Accepts TransCon® CNP NDA for Priority Review

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to FDA Accepts TransCon® CNP NDA for Priority Review

Ascendis Pharma (ASND) PT Raised to $201 at BofA Securities

June 2, 2025 12:02 PM EDT

BofA Securities analyst Tazeen Ahmad raised the price target on Ascendis Pharma (NASDAQ: ASND) to $201.00 (from $196.00) while maintaining a Buy rating.

The analyst comments "Ascendis (ASND) announced the NDA submission for TransCon CNP in achondroplasia (ACH) was accepted by the FDA with priority review with an assigned... More